ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have earned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $77.00.

A number of research firms recently commented on ANIP. Raymond James lifted their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a report on Wednesday, September 18th. Truist Financial reiterated a “hold” rating and set a $60.00 target price (down from $80.00) on shares of ANI Pharmaceuticals in a research note on Wednesday, September 11th. HC Wainwright reissued a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Tuesday, September 17th. Piper Sandler assumed coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 price target for the company. Finally, StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th.

ANI Pharmaceuticals Trading Up 0.3 %

Shares of ANI Pharmaceuticals stock opened at $60.31 on Friday. The stock has a market cap of $1.26 billion, a P/E ratio of 37.69 and a beta of 0.71. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. ANI Pharmaceuticals has a 12-month low of $48.20 and a 12-month high of $70.81. The business’s 50 day moving average is $59.49 and its 200-day moving average is $62.39.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The firm had revenue of $138.00 million for the quarter, compared to analyst estimates of $129.09 million. During the same period in the prior year, the firm posted $1.06 earnings per share. The company’s quarterly revenue was up 18.5% compared to the same quarter last year. Equities research analysts predict that ANI Pharmaceuticals will post 3.58 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ANIP. Exchange Traded Concepts LLC boosted its position in shares of ANI Pharmaceuticals by 20.8% in the third quarter. Exchange Traded Concepts LLC now owns 12,056 shares of the specialty pharmaceutical company’s stock valued at $719,000 after acquiring an additional 2,072 shares during the period. Kings Path Partners LLC boosted its holdings in ANI Pharmaceuticals by 18.9% in the 3rd quarter. Kings Path Partners LLC now owns 19,418 shares of the specialty pharmaceutical company’s stock valued at $1,158,000 after purchasing an additional 3,086 shares during the period. Susquehanna Fundamental Investments LLC acquired a new position in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $228,000. The Manufacturers Life Insurance Company increased its holdings in shares of ANI Pharmaceuticals by 14.6% during the second quarter. The Manufacturers Life Insurance Company now owns 9,498 shares of the specialty pharmaceutical company’s stock worth $605,000 after purchasing an additional 1,211 shares during the period. Finally, Millennium Management LLC raised its position in shares of ANI Pharmaceuticals by 1,005.8% in the second quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock valued at $14,651,000 after buying an additional 209,272 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.